hatchtech ::
   
hatchtech australia contact
Hatchtech :: INSECT CONTROL FOR A NEW ERA


INVESTORS
Hatchtech investors include some of the largest and most influential life sciences investors in Australia:

Biocomm
GBS Venture Partners
Queensland Biotechnology Fund
Uniseed
Westscheme

BOARD
Hatchtech has an experienced board of directors with skill sets and backgrounds spanning science, finance, business development, drug development and agricultural technology. The members
of the Hatchtech board are as follows:

Dr Andrew Baker
Dr Vern Bowles
Mr Lawrence Bremner
Mr Terry Bunn
Dr Paul MacLeman

Dr Stewart Washer (Chairman)

 

 


MANAGEMENT
Hatchtech's management team is a small but focused group that is leveraged by use of a global network of drug development, crop protection, veterinary, regulatory
and commercial contractors and advisors. 

Hatchtech's management team are:

Dr Paul MacLeman
CHIEF EXECUTIVE OFFICER
Paul is a veterinary surgeon (BVSc,University of Sydney) and has additional qualifications including  an MBA (MGSM),  Grad Dip Tech Mgt (Risk & Valuation), Grad Cert in Eng (Process Design & Control), and is a Fellow of the AICD. He is also past director of the Veterinary Manufacturers and Distributors Association and a serving member of the Ausbiotech AgBiotech Advisory Committee.

  Paul's previous roles have included Chief Operating Officer for Imugene Ltd where he was responsible for re-focussing the company's commercialisation strategy & systems and evaluating new opportunities. Prior to this Paul was Vice President of Agenix Ltd, heading their global veterinary immunodiagnostics business and was part of the senior leadership team. Here he gained experience in managing global business units and on-market product portfolios. Paul also has experience in founding life sciences start-ups and has worked in Investment Banking focusing on the analysis and financing of technology companies.


Dr Vern Bowles: 
CHIEF SCIENTIFIC OFFICER
Vern is the founder of Hatchtech and the research underpinning the core intellectual property is the culmination of 15 years of his work. He has devoted a significant proportion of his research career to studying the role of ectoparasite proteases in parasite infections, parasite nutrition and immune evasion. This work has been extended to the role of proteases in egg hatching in the sheep blowfly, head lice and other pests. Vern is an integral part of Hatchtech where he is responsible for the emerging crop, household and veterinary programmes and is also playing an important role in the back-up screening for new compounds for the head lice program. Vern is also the Deputy Director of the Centre for Animal Biotechnology in Melbourne.

Dr Maria Dynon 
REGULATORY AND CLINICAL MANAGER
Maria has over 25 years varied experience in the pharmaceutical industry, including three years as a TGA preclinical evaluator and over 11 years as a consultant to the biotech and pharmaceutical industry with Kendle International Inc and its forerunner, Synermedica.  Maria also spent nine years at the Therapeutic Goods Administration managing registration applications in Australia, including twelve successful registration applications for new chemical entities.  Prior to this, Maria worked as a product manager/group product manager for the multinational research-based pharmaceutical company Farmitalia Carlo Erba (now part of Pfizer), during which time the company launched four new chemical entities in Australia.



Dr Lewis Schulz
CHIEF OPERATING OFFICER
Lewis has more than ten years first hand local and international experience with drug and device development. This has included the transfer of a new anti-inflammatory agent from the laboratory to the clinic and in this role he was responsible for the management of preclinical and clinical development activities. His previous experience also includes roles focussed on chemistry, manufacturing and regulatory affairs, and six years in European posts with international pharmaceutical companies. While working for Bristol Myers Squibb International, Lewis was instrumental in development and implementation of regulatory and marketing strategy for their oncology portfolio in the Central and Eastern European region.

 
 
 
© 2006 HATCHTECH